Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TPH1 | P17752 | 4/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22189969 | 1.00 | KMT2A (0.57) | KMT2AKCNA5KCNH2NOS3NOS1 | |
| SCHEMBL6171071 | 0.89 | KMT2A (0.71) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL16967410 | 0.89 | KMT2A (0.71) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL19667642 | 0.89 | KMT2A (0.71) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL22190043 | 0.85 | KCNA5 (0.63) | KMT2AKCNA5KCNH2NOS3NOS1 | |
| SCHEMBL22190042 | 0.85 | KCNA5 (0.63) | KMT2AKCNA5KCNH2NOS3NOS1 | |
| SCHEMBL31631338 | 0.84 | KMT2A (0.64) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL31370463 | 0.82 | KMT2A (0.57) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL7263124 | 0.82 | KMT2A (0.57) | KMT2ANOS3NOS1NOS2ALPI | |
| SCHEMBL14863029 | 0.80 | KCNA5 (0.54) | KMT2AKCNA5KCNH2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | KMT2A 4390/4885KCNA5 1210/4885KCNH2 1806/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | KMT2A 4279/4885KCNA5 697/4885KCNH2 1559/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | KMT2A 4390/4885KCNA5 1210/4885KCNH2 1806/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | KMT2A 4390/4885KCNA5 1210/4885KCNH2 1806/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | KMT2A 4318/4885KCNA5 1129/4885KCNH2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.